Discussion page for Arch Therapeutics (ARTH)This page is for discussion of Arch Therapeutics (ARTH).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Just came across this. Haven’t seen it posted here. https://www.zacks.com/research/get_news.php?id=6x79pzulaq
I’m pretty sure this was previously posted Kristi lie. Not in $ARTH anymore, but cheering for those of you who still are
$ARTH wow > 10-Q for the quarterly period ended March 31, 2018
https://ir.archtherapeutics.com/all-sec-filings/content/0001144204-18-022685/tv491272_10q.htm Let’s get this party started. 🙂 #Best2ALL! 🙂
$ARTH atlas ow
what to expect of $ARTH, Gr8Full? nothing much happening before the ongoing “small, three-month long, non-invasive human study to provide the additional data to the FDA” is finished? or am i missing something?
He’s just being a prick. He left the stock long ago. I guarantee ya he doesn’t even own a share.
I personally don’t think the science has changed. And – It is a low funded start-up biotech. Take your chances obviously.
And I guess we will see who comes out on the top at the end.
Blackngold63. Are you talking about the guy looking back at you in the mirror?
i sincerely wish you’d stop talking bad about probably the best contributor this site has ever had. Gr8tFull is on top of so many things most of us can’t even begin to comprehend so i’m afraid you comment is way out of line.
Only you are responsible for your acts, no one else.
Rest of your comment i agree with.
Just another troll
I started thinking about re-investing in ARTH after reading the 5/8/18 ARTH press release:
“Arch intends to initiate the [sensitization] study in the next few weeks incorporating FDA’s comments and ….. expects to file the 510(k) notification in the third calendar quarter of 2018………..We still expect the trial to cost approximately $100,000 and take about three months.”
Doing more research, I found that Arch Therapeutics Initiated a Clinical Trial of AC5 in Europe back in December, 2015 — https://www.fdanews.com/articles/174554-arch-therapeutics-to-initiate-clinical-trial-of-ac5-in-europe .
I could find no reference to this trial on the ARTH website. Googling the topic, I found a link to it on their website, but the link said “the page you requested could not be found”.
I also found “The British Standards Institution Classifies Arch Therapeutics’ AC5™ as a Medical Device Within the European Union” [ dated 2/17/15 ] at http://www.marketwired.com/press-release/british-standards-institution-classifies-arch-therapeutics-ac5-as-medical-device-within-otcqb-arth-1992207.htm
There being no information on the ARTH website seems very strange to me. Does anyone remember anything about a European trial or approval?
$ARTH atlas ow
hipockets, please do share your thoughts, if you have any more, regarding ARTH and latest press release 🙂
I thought it was promising, as always, so wasn’t particularly thrilled and will wait for actual actions to be taken by the company and results to be seen. Will not trust plain words anymore.
finventurer, if ARTH begins the three-month study on skin sensitivity to settle the only remaining outstanding issue for FDA approval, does that count as an “actual action?”
i believe it does, JohnM 🙂
hipockets, Arch PR’d the results of the clinical trial here:
ir.archtherapeutics.com/press-releases/detail/483/arch-therapeutics-reports-ac5-topical-hemostatic-device
They then PR’d the peer-reviewed publication of the complete results here:
ir.archtherapeutics.com/press-releases/detail/502/dermatologic-surgery-publishes-clinical-data-on-arch
Thanks for the (no moderatatatater) links. 😉
$ARTH Thanks, JohnM, for the links. Your info gave me impetus to search for “ARTH CE Approval”.
In their 3/12/18 press release, they stated “Arch also expects to file a CE mark in Europe for AC5 in the second half of 2018.” They have been saying they plan to apply for CE Approval every year since 2015, but they never explained why they did not file during those years.
I emailed their IR department, and received this reply: “It is not approved in Europe yet but they are looking to gain the CE Mark in due course.”
Not very informative . . . .
At today’s prices, I feel the risk of investing in ARTH is small, but the rewards of the science (and everything I’ve read says the science is good) can be huge. But why did KSS go ballistically negative about it? With his mental instability, perhaps it was over nothing important. ( I hate to think that AlanH was barred from Gumshoe over nothing important !!!!!! )
But the history of management bothers me. It seems to me they promise a lot, but don’t deliver a lot. Maybe it’s just a matter of poor communicating on their part, or poor understanding on mine. But someone once said, on the first ARCH thread, paraphrasing, “Norchi just wants to travel from conference to conference and draw his salary”. That might or might not be true, but I’m beginning to agree with it.
AlanH tried to teach us to conserve our capital. I think I will hold off on re-investing until they actually re-file the 510(k), which they say will be in 3Q2018. I might miss a big pop, but there should be large gains after the pop.
If anyone thinks I’m being too negative about ARTH’s management, please tell me.
P.S. If I were already invested, I would stay the course. But that’s me.
[ For those of you unfamiliar with “CE Marking”, see http://www.ce-marking.org/what-is-ce-marking.html . ]
Hipockets I cannot disagree. I have long felt that Norchi is not really able to shepherd #ARTH to market.
I hold far too much now and am at loss but still hopeful.
Same story for most of my bio.
arch1, do you fell Norchi is unable to oversee a three-month human sensitivity trial, or do you think Norchi is not capable of negotiating a distribution deal? Or do you see some other obstacle keeping AC5 from the market?
hipockts, I think you are being much too negative about ARTH management. (I am very OW.)
1. They did explain why they didn’t file for a CE mark. Their manufacturer told Norchi when they would file, which Norchi repeated to investors. The manufacturer then filled out the forms for a drug filing, which is what they were used to. But AC5 is a device, so they missed their timing.
Having said that, I have no idea why it has taken this long for the manufacturer to prepare the correct filing form. I suspect it was unfamiliar to them and required some documentation they don’t normally have. Norchi hired a QA person to make sure this doesn’t happen again.
2. KSS went ballistically negative after a member of this forum spoke directly to Norchi’s FDA consultant and posted her comments here. She never should have spoken to him. KSS says Norci called him and held him responsible for the call to the consultant, which infuriated KSS and caused him to say he was abandoning the stock. Norchi has indicated that isn’t what happened in the call. I suspect the truth lies in between. Norchi can’t discipline his consultant because she literally wrote the book on how to get a medical device approved. But like any CEO, he wants to control the company’s interaction with Wall Street and investors.
3. I believe the idea that “Norchi just wants to travel from conference to conference and draw his salary” is absolute hogwash. Norchi gave up a powerful position and multimillion-dollar annual compensation as the manager of Putnam’s healthcare fund to spend 10 years getting AC5 to market. He owns 13% of the company and that decision only makes sense if he walks away with $100+ million. He isn’t doing this to laze about on shareholders’ capital – he wants to be successful and rich (as KSS pointed out early on).
4. Cleveland has shown us over and over how capital-efficient and parsimonious Norchi is with the capital he’s raised. I think he’s made four mistakes executing at Arch:
a. He repeated what CURAM told him about when they would start the clinical trial, instead of just saying it was in their hands, and lost some credibility when they missed their timing.
b. He trusted the manufacturer to properly fill out the application for CE mark approval without any oversight by ARTH because he was trying to save money by delaying hiring a QA person.
c. He did not run a human sensitivity trial before applying for 510(k) approval.
d. He PO’d KSS by whatever he said in the contentious phone call.
All of these mistakes are recoverable errors. He’s been pretty good about building an investor base that will support him through warrant exercises and a careful ATM arrangement, as you would expect of an MBA with a high level of financial sophistication. This is still a stunning technology with 200+ applications. Approval is delayed but, in my opinion, certain. So it is just a question of diluting himself and us as little as possible until he can start signing distribution deals – which could happen any day, or not for 6 months to a year.
John – Many of us have been aboard ARTH for most of its circuitous journey and have heard most of the “stories”. Congratulations on your well thought out comments and observations, supported by a plethora of facts and details. It was a pleasure to read and makes a strong case. Thanks for your efforts to provide it.
$ARTH — JohnM — Thank you for your excellent post. We all have heard about the “Gummy Bounce” – I think we saw a “JohnM Bounce” today! 🙂 Please keep commenting! 🙂
$ARTH
Nice post JohnM $ ARTH up 19 % !!!!!!!!!!!!!!!!!!
I got evicted from Dr. KSS’s forum. I have no idea why. He just canceled me out.
Such is life.
Always good to hear from you Cleveland.
$ARTH
I’m actually above water on a couple of my accounts with this improved stock price. (Makes fervent prayer to the gods of the markets for continuation of this state of upness.)
Cleveland, I’m shocked that you were evicted from The Other Forum. Although a member, I haven’t been there for a little while as I have a life outside of taking care of my little stock portfolio and this is peak busy time.
I’m always glad to see your posts here.
Penny
Wait! What? YOU got banished? I thought you were his right hand man? I always knew he was a prima donna but it’s become more evident he may be bipolar or something. Wondering if I should continue to listen to his musings….
$ARTH
I’m shocked … like Dzurej, I thought you were one of KSS’ go-to guys. Hard to tell what sets him off at times. I’ve done fairly well following his coverage but am always hesitant to comment because of what appears to be a very quick temper.
In any event, I’m always happy to read your insights.
OW ARTH
I’m not surprised. Science and Product are not the sole prerequisites for a successful Biotech. Management and finance are a good part of the remainder for success. Cleveland you have the best knowledge I’ve seen on Management and Finance undoubtedly due to your experience.
Hi Cleveland,
Thanks for posting, hope you can post here once in a while if you feel like it.
Still long ARTH and hope they can refile 501k by 3rd quarter.
Hi Cleveland,
KSS’s website is under construction and rebuild for a newer and better site. Could be a day or two but try to log on again soon.
$ARTH – Long
Biting the hand that feeds him appears to be a pattern. Considering all you have done for him over the years, I find that news appalling. I hope it’s a mistake. I may not always agree with your posts, but no one can argue the fact that that such posts are thoughtful, detailed, and well intentioned. It’s obvious you invest a lot of time. Despite publicly disparaging remarks made about this forum by a former contributor, and I might add, beneficiary, this forum provides an open dialogue where civil discourse is encouraged. Good to have you posting here again about $ARTH. I suspect we are in for some news about financing shortly. We’ll probably hear about the exercise of some in the money warrants, and possibly a private placement or secondary offering.
Cleveland. Did you try to log on yesterday or today and get a messages that said, “This website is currently unavailable”?
If so, you weren’t banished. Everyone gets this page at the present time due to construction on his site.
If not, and if you were truly banashed, then I’d love to know why. You have been invaluable in your analysis here and were KSS go to guy for all things ARTH. I hope it is the former.
Cleveland, totally agree, not only with ARTH, but CLRB and others to numerous to mention. I miss your invaluable insight.
Rich
Hey Cleveland. On one of his CC, KSS, near the start (so maybe was not on record at the time – I have not listened to playbacks for a while), said what a good person you were and was hopeful that you would return to his site. He implied you two might have had a disagreement but never said that. In so many words, he said he respected your opinions and comments! And that he hoped he would see you back! That you are welcome back at any time. I believe this must have been about the first of May/maybe the private placement investment talk with a certain company. Hope you see this and will stick your head in again at the KSS forum. (please ignore if this has already been repeated to you).
Long time lurker here.
Was curious as to whether anyone had any insight into the following excerpt from $arth’s 2017 annual report that covers their ability to gain additional financing:
“…we may continue to seek funding through additional collaborative arrangements with strategic partners if we determine them to be necessary or appropriate, although these arrangements could require us to relinquish rights to our technology or product candidates and could result in our receipt of only a portion of any revenues associated with the partnered product. We cannot provide any assurance that additional financing from these sources will be available on favorable terms, if at all. In addition, we are bound by certain contractual terms and obligations that may limit or otherwise impact our ability to raise additional funding in the near-term including, but not limited to, provisions in the Securities Purchase Agreement that we entered into on February 20, 2017 (the “2017 SPA”) in connection with the registered direct financing that closed on February 24, 2017 (the “2017 Financing”). In particular, certain provisions within the 2017 SPA restrict our ability to effect or enter into an agreement to effect any issuance by us or any of our subsidiaries of Common Stock or securities convertible, exercisable or exchangeable for Common Stock (or a combination of units thereof) involving a Variable Rate Transaction (as defined in the 2017 SPA) including, but not limited to, an equity line of credit or “At-the-Market” financing facility until the three lead investors in the 2017 Financing collectively own less than 20% of the Series F Warrants purchased by them pursuant to the 2017 SPA. These restrictions and provisions could make it more challenging for us to raise capital through the incurrence of additional debt or through future equity issuances. Further, if we do raise capital through the sale of equity, or securities convertible into equity, the ownership of our then existing stockholders would be diluted, which dilution could be significant depending on the price at which we may be able to sell our securities. Also, if we raise additional capital through the incurrence of indebtedness, we may become subject to covenants restricting our business activities, and the holders of debt instruments may have rights and privileges senior to those of our equity investors. Finally, servicing the interest and principal repayment obligations under any debt facilities that we may enter into in the future could divert funds that would otherwise be available to support research and development, clinical or commercialization activities.
If we are unable to obtain adequate financing on a timely basis or on acceptable terms in the future, we would likely be required to delay, reduce or eliminate one or more of our product development activities, which could cause our business to fail.
The terms of the 2017 Financing could impose additional challenges on our ability to raise funding in the future. ”
Given that all signs point to $arth running out of cash by EOY at the latest (end of Q3 more likely), does anyone have any thoughts on how this would be approached?
Thanks in advance
link:
https://ir.archtherapeutics.com/annual-reports#document-11056-0001144204-17-059213
$ARTH OW
Welcome JMBanks44.
Did you wave your magic wand over $ARTH this morning? I’m not holding my breath, but it’s nice to see a little rise in the SP.
Penny
Thanks, Penny.
If only I had such a wand, I would have used it much sooner! I agree though, it is good to see the positive turnaround on the SP.
That said, as quoted in my previous post, I’m a little wary of what is to come in the next 6 months in terms of financing. I’m new to Biotech, but for any sector, not being able to raise capital at such a crucial time in the company’s road map seems to be a major red flag. Have you or anyone else on this SG thread seen this kind of verbiage in regards to financing restrictions?
$ARTH I might be wrong J-M but I think this is possibly part of the standard verbiage which companies use in their reports to cover their backs just in case things go horribly wrong, such as eg the following excerpt taken from $Auph’s most recent annual report – “However, if capital market conditions in general, or with respect to life sciences companies such as ours, are unfavorable, our ability to obtain significant additional funding on acceptable terms, if at all, will be negatively affected. Additional financing that we may pursue may involve the sale of Common Shares which could result in significant dilution to our shareholders. If sufficient capital is not available, we may be required to delay our research and development projects, which could have a material adverse effect on our business, financial condition, prospects or results of operations.”
$ARTH ow > Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
Click to read the full article https://ir.archtherapeutics.com/press-releases/detail/506 Have a great day and beyond ALL! 🙂
FRAMINGHAM, Mass., May 15, 2018 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 8th LD Micro Invitational. The conference is being held on June 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Terrence W. Norchi, MD, CEO is scheduled to provide a corporate update on Monday, June 4, 2018 at 8:30 AM PDT. Dr. Norchi will be available to meet with investors who are registered to attend the conference. If you are an investor and wish to attend the Company’s presentation or schedule a meeting, please click the following link: https://www.ldmicro.com/events…
#8th LD Micro Invitational – June 4-6, 2018 – Luxe Sunset Boulevard Hotel in Los Angeles, California. (Ben – thanks for posting)
Is anyone from this group registered to attend? (Or from Another Group?)
Penny
Arth OW, nice to see stock price climb back over .40 again..Hopefully get back to it’s old highs and beyond on FDA approval…
$arth chart stand point,,,,, arth has built a base and is likely to fill the $.70 gap.
The volume is confirming the up move.
KSS stated he will review ARTH in July
but does it matter??????
Houston we have lift off.
$ARTH atlas ow
Rumrunner, i don’t wish to be mood killer here, but if you check out the chart of $ARTH you’ll see that these kind of lift-offs have happened before and for example corporate updates by CEO have had opposite impact on SP in the past. those of us who have followed company for several years now remember how painful it can be to see your gains slipping through your fingers without any obvious reason.
As far as i’ve understood there’s practically no institutional money to support the SP, just a few big bigger players, so we are still in control and our mood swings push the SP accordingly.
i too have my fingers crossed but wouldn’t hold my breath if i was you. i trust the science in this one, everything else is debatable.
Best of luck!
yours, Finn.
$arth
Gaps are filled 91.4% of the time. $.70 is the target gap. Believe the price is in the process of discounting application and approval of AC5.
Price and volume action is working in the short term.
Stats on institutional ownership will likely effect ARCH after FDA approval. A reverse split would ?????????????
$ARTH atlas ow
All of those you mentioned would have an positive effect on share price, market sentiment, recognizablity towards Arch Therapeutics for sure, you’re right.
But last time CEO stated now is not the time for reverse split – and probably won’t be for some time. and before reverse split there’s probably not going to be any institutional ownership either since shares need Nasdaq listing first. Institutions aren’t interested in OTC-listed companies due to their own regulations. Or at least we need to see quite a lot more buying from us small timers in order for Arch to meet the Nasdaq requirements.
Hold your horses, it’s a long flight to the end of the rainbow – but a rewarding one, i bet, at the end.
At the LD Micro Conference this morning, Norchi said they will start the sensitivity study in June, complete in three months, file for FDA approval before the end of September, and file for the CE Mark in the second half of this year.
If I’m being honest, I was a little disappointed that he mentioned they will start it this month, and that they have not already.
Given that they have worked with the FDA to design the study to address their concerns with the previous application, is it safe to say it’s likely they would be approved if the test results come back positive?
Will be interesting to see where the SP goes if that is the case.
Because this was the only issue the FDA had and because they have approved the study design, I expect a positive outcome to lead to approval. One question is whether the FDA will give them a two-month review instead of the usual six months for a new 5120(k) application.
I don’t remember what that short time was but it was available. Since the start is this month that time should be known or on the request form for the trial.
The trial is 90 days long. I am talking about the length of time the FDA will review the refiled 510(k) application before giving ARTH final approval.
That’s a great point John, I didn’t take that into account. One would hope if all aspects of the application are the same as the first go around, minus the inclusion of the study results of course, that the FDA would give them an expedited review.
Again, this is my first foray into Biotech, but ss the CE Mark more difficult to achieve? Would an FDA approval lock in a positive CE Mark application?
No, the CE Mark is a safety approval that is much easier to get – you don’t even have to do a clinical trial. (But you have to get approval from each individual country for reimbursement, and good luck getting that without strong clinical results.) An FDA approval would indicate there will be no safety issues for the CE Mark.
ARTH’s problem was that the AC5 manufacturer filled out the wrong paperwork for the application, completing the drug application they were used to instead of the device application that covers AC5. I don’t know why it has taken the manufacturer so long to complete the right paperwork, but my guess is that it required data they don’t normally collect for a drug, so they had to start from scratch.
Some folks blamed Norchi for the manufacturer’s mistake. He was trying to save money for the shareholders but relying solely on the manufacturer went awry. He has hired a Q&A person to make sure nothing like this happens again.
$ARTH
John, thank you for this very complete explanation of the situation at Arch. Now I much better understand the “what”, but am left wondering about the “why” – “Only the Shadow Knows”
” I don’t know why it has taken the manufacturer so long to complete the right paperwork, but my guess is that it required data they don’t normally collect for a drug, so they had to start from scratch.”
I would imagine they realized it was screwed up. Meaning Arch. And decided to move on to getting other ducks in a row before re-submitting. Meaning patents and the FDA one. You might look at it as a learning experience. They wanted it to happen – it didn’t – but not a big deal because on to bigger fish. It will happen.
You are right. As soon as Norchi realized the CE Mark would be delayed, he split the planned FDA filing into two parts, a 510(k) for external use that could be approved relatively quickly, and an IND for internal use that will require another clinical trial. Then the FDA threw a spanner into the 510(k) process and here we are – everything on track but one year late.
John, Peter, and BlacknGold-
What are your thoughts on funding? Looking at the last quarterly report, it seems as though they have just enough cash to get through September, if they are lucky. TIA
$ARTH
Correct. He will have to raise cash soon. I expect him to go to his current investors to either reprice old warrants so they exercise them now or maybe do a convertible bond. But he could have to do a stock sale. That would come after they PR that the sensitivity study has started.
$ARTH: We have all wondered out loud how the manufacturer could have made the mistake, and also why it has taken so long to correct the mistake. Does anyone wonder why CEO Norchi or his QC guy never attempts to answer these questions for us?
Long $MEIP;MEI Pharma (NASDAQ:MEIP) was upgraded by analysts at Wells Fargo & Co from a “market perform” rating to an “outperform” rating. current price of $4.90.
NP $MRNS;Marinus Pharmaceuticals (NASDAQ:MRNS) is now covered by analysts at LADENBURG THALM/SH SH. They set a “buy” rating and a $20.00 price target on the stock. 189.0% upside from the current price of $6.92.
NP $AKBA;Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at HC Wainwright from $24.00 to $22.00. They now have a “buy” rating on the stock. 127.0% upside from the current price of $9.69.
Regards,
Frank
#LightBulb > The most significant and difficult aspect of investing/trading in biotechnology is #size, position, timing, maintaining dry powder, blood, sweat and tears. * Otherwise, it’s similar to https://twitter.com/H0U3/status/1004493764516372482
Wow! $ARTH, the Gr8 #Gummunity! 🙂 #Best2ALL! 🙂
* i.e. $PTI from sp at $4.90 to +10x at $2.95 to currently $4.25 AH
Ling Arth
Wow Arth is right – what happened today that it dropped over 18%?
#Tunez and investing > The Moment https://www.stockgumshoe.com/2016/05/microblog-magical-music-mystery-mining/comment-page-4/#comment-4982958
#Long #Gummunity $arth!
#InPlay > https://www.stockgumshoe.com/2017/11/microblog-pre-and-after-market-discussion-thread-xyz-or-subject-reqiuired-in-each-post-tia/ Share and care! 🙂 #Best2ALL! 🙂
* Remember to subscribe to the threads you are interested in.
Norchi said he will start the sensitivity study in the next three weeks, but he didn’t say he had started it already, so those who were expecting the “already” announcement sold. I guess they think they are clever enough to buy it back before he makes the announcement, which could come any day – assuming he puts out a press release.
Or, the total $value of all shares traded yesterday totaled just $200k. I’m in a small stock club that owns 5X that many. This could be 1 single investor or small group simply deciding to play somewhere else for awhile. 🙂
Even worse, NASDAQ double-counts each trade. You sell 100 shares to a market maker and they sell those 100 shares to me. NASDAQ reports 200 shares traded, even though only 100 shares moved from one holder to another. So really only $100,000 of ARTH traded on Wednesday. Of course, real average volume is under $50,000 a day.
I sell all at breakeven, no steam it’s like a dead stock.
$ARTH long
marcello “I sell all at breakeven, no steam it’s like a dead stock.”
Did you sell?
$ARTH PR regarding the start of the skin sensitization study:
https://ir.archtherapeutics.com/press-releases/detail/507
Considering Norchi states in the PR that the test takes about three months AND they expect to file for the 501(k) by end of Q3, it will be a tight turnaround to have the application in post-study results. Here’s to remaining optimistic!
$ARTH long. In addition to the two-week turnaround to get the 510(k) filed by the end of September, Norchi committed to file the CE Mark application around the same time – he said it is a “second half event.”
Also, he said “around the end of the year, the start of the year” he expects FDA approval. To me, that means the FDA has indicated Arch will get a very fast three-month decision, instead of the usual six to nine months.
Norchi said the FDA indicated there are no other areas of concern besides the sensitization trial.
Arch had $3.4 million in cash at the end of March and a burn rate of $1.6 million a quarter. They have about $4 million in warrants in the money and a supportive shareholder base, so there is a chance they won’t have to do another capital raise until after AC-5 is approved. Norchi owns 10% of the company and other insiders own an additional 10%. I suspect they want to avoid dilution as much as we do.
$ARTH
Hearing bits and pieces of the fairy tale about me in the Den. It all news to me. This is Fake News at most.
We have strong slander laws in this country. Looking forward to obtaining the entire written fairy tale and especially the emails among the group of six about me. (Please do not delete them). This is all part of a campaign to discredit me. There is a reason for it……….
He is soooo gifted but has a very strong need to discredit and trample others who are also gifted to make himself feel superior. I was always aware of it and uneasy and he would scold me in emails to ease up. We have seen this happen multiple times in last several years. Over and Over and Over. He even takes on biotech professionals on a regular basis. Not good for reputation I would think.
BTW I bet you are seeing more financial comments from him and in my world they do not hold much water. Before he dropped me for no reason I did see his critique of the “Cleveland Ratio.” I did a very poor job of teaching to him because he was way off base.
Been here since 2014. Always said thousands of times I do not care whether you own or not $ARTH. Does not matter. I do not care. Over and Over and Over. Please reread this.
Fortunately it is all here and cannot be erased. Thank Goodness. You have to sell a share to deal in his fairy tale. What financial gain?
I do not believe it would not even be possible. It is so far fetched. Hopefully he completes his fairy tale.
What I said here about $ARTH was but a small fraction of the positives spewed by Doc. It is all HERE. Mine was all about financial information. Never a recommendation to buy or sell by me. EVER ! That is a fact. I have kept EVERY SINGLE post and EVERY SINGLE email. Organizing it all now.
Perhaps I need to reference the hundreds of $ARTH positive comments he made. He fostered the $ARTH buying based upon his comments. Mine were financial and a mere shadow of his.
I am the person who raised $27,684.44 for travel expenses in 2017 from 105 people. I am the person who wrote a check for $ 1,000 to him. I am the person who found Cohbar CWBR. I was in his group of six and know everything about it. I assisted in getting the present website up and running and obtained many of his documents for Paypal to begin functioning. Has anyone done more than I? He cannot rewrite what happened so he can feel superior. Just not going to happen. Everyone knows the truth because it is all here.
Unless you want to be thrown out of the Den please do not comment. I will not comment also. I do not want anyone harmed like I have been. If you want to comment on anonymous basis email: nevas123@aol.com
I will have a post on CLRB next.
$CLRB
Looking forward to your post on this stock. Thanks in advance, Cleveland.
deleted
Cleveland gave an email address at the end of his post, and indicated that he didn’t want to post more on the topic. If you feel you really need clarification, why not contact him by the way he provided?
Good point, catherine. My reading comprehension pre-coffee is abysmal.
#Personally, I do not care for being told what to to.
This Alpha male crap is part of what obliterated the #Gummune, imho.
To moi, $ARTH has and shall continue to be nothing more than a distraction, with large opportunity costs, IF you let it be, until tn decides to shift gears. I have removed it completely from my primary portfolio and currently hold many shares. #Best2ALL! The #Gummunity lives on! Maintain your focus! #AvoidTheNoise
$ARTH
Just digging through the files here. Amazing what was said of $ARTH. All here. All documented. Summarizing everything. I would think this kind of discussion would generate some buying then. More on that later.
What I said was tame. It was all financial. Never any recommendation to buy or sell.
“We get to cover and track a lot of cool stories here, but this is still the most important biotech storyline of our time in my opinion. Long $ARTH.”
“But in Arch’s case, in every instance, they are thinking fully, they are dreaming big. They plan to wreak themselves upon life with AC5. Whether your premise is sell-side or buy-side, these shares seem a ridiculously good place to be. They won’t pay off gradually, but rather the rewards will come in epochs, as seismic shifts occur in Arch’s landscape as a result of its labors.”
“I still think ARTH is doing primo science. It’s among the best protein chemistry in the history of mankind.”
“Arch is in full possession of the most fundamentally brilliant piece of protein chemistry any of us will see in our present lifetimes.”’
“Arch has the product there that will fundamentally revise the practice of medicine more than any other, and attendees saw it not, didn’t get it, and not because Terry withheld that from them. If you have no contextual frame of reference you don’t know what you don’t know: you don’t realize that a surgeon spends 40 percent of his time STOPPING BLEEDING and that it’s damned tedious and that it drives up costs of care, as surgery is billed by the minute. What if we could reduce the cost of surgery on average by 1/3 for each case (admittedly offset by the price of AC5, but I predict AC5 will cost less than the value of the surgical time saved).”
Re: Dr. Norchi: “….he is the perfect CEO, and very much a physician at heart as well.”
“I have a PhD in the molecular mechanisms of hemostasis and I KNOW it will work.”
“I’ll declare it loud and clear: I have read many papers on the actions of AC5 and seen video footage of it being used in animal surgery, and it is the most impressive idea and product I have ever seen in 20 years of biotech investing. It seals wounds and halts bleeding and oozing within seconds, even when the animal is on blood thinner. It could halve surgical times, as an average operation has the surgeon spending half his time addressing bleeding (some forms of surgery, such as orthopedic procedures and liver surgery, are even more bloodletting). It could slash operating room times and the need for perioperative blood transfusion.”
“I can tell you from my perspective as someone whose PhD was in clotting biochemistry, I am sure AC5 will work in humans.”
Arch’s “family of peptides are truly among the most remarkable biochemical inventions of all time.”
AC5: “Spray it on a bleeding artery and the bleeding stops without mechanical pressure being needed.”
“Arch’s AC5, a aqueous hemostatic agent that may halve surgery times, reduce requirement for peri-operative blood transfusions, halt GI bleeding, shine for battlefield trauma, and even enable surgery without reverse anticoagulation for patients on blood thinners.”
“It doesn’t cause clotting in those who cannot clot, but creates a tightly apposed tissue barrier that vessels cannot bleed through. Not to sound like a shill for Arch, but this is a new paradigm for medicine.”
“Norchi alluded fairly early in the conference to the fact that he anticipates Arch will very soon by facing the mammoth issue of having marketing authorization in the EU and thus needing partnering to move forward.”
“Arch’s AC5 is hemostatic, not coagulative. The others are coagulative and incur serious problems.”
“I am long $ARTH for one reason: AC5 is the most brilliant such product ever devised, and because I believe that if ever there was an entrepreneur with the cojones, vision, and fussy commitment to detail to really drive this company up into the stratosphere, that person is T. Norchi.”
Dr. Nochi: “is having to invent an entire universe, people. Being God is hard work. He has to get people to buy into a concept totally new for medicine, and has to take the brunt of the fact that most lack the sophistication to be thrilled by Arch’s work (not speaking of readers here….”
“Arch “they have other self-assembling peptides that promote wound healing as a scaffold…. Unless the laws of chemistry and physics change, failure will not happen.”
“When Arch shares begin to march up, they may not do so in an orderly manner. But when, if ever, any of us enter ARTH shares, is something we need to brood on as a group.”
“The number of prospective life-saving and health-facilitating uses of AC5 is enormous. And not only for surgery. GI endoscopists often are scoping to find a source of bleeding and fix it….ulcers (Foot ulcers $ 15 billion market), varices, mucosal tears, Dieulafoy lesions. When we remove polyps, we often leave behind a stalk or base that requires injections of epinephrine (to trigger platelet clumping and cause vessels to clamp down) and thermal cautery with probes.”
“Not only could it serve as a sealant in any surgical situation, I was particularly excited by the boon it could be for liver surgery. Occasional diseases call for masses to be removed from the liver, and this operation is particularly challenging. Blood mostly percolates through the liver in so called sinusoids, channels via which certain substances are removed and others added. Incise the liver, and the sinusoids begin to ooze profusely. Moreover, microscopic bile ducts begin leaking bile, and bile splashing onto peritoneum is exquisitely painful. And bile, being in communication with the GI tract, is not sterile. Liver surgeons spend extraordinary hours of time standing in place and using cautery devices to char and sear the liver so that bleeding and oozing stop. They emerge from surgery smelling like burning flesh, the exquisite horrible smell I once experienced from being near a Hindu riverside funeral pyre in Nepal. AC5 would literally revolutionize liver surgery.”
“In the 1990’s a company called Closure Medical Corp lay claim to medical epoxy glue as a new class of medical sealants. Closure was acquired by Johnson &Johnson in 2005 for $ 370 million. One of the key executives of Closure, William M Cotter is now Chief Operating Officer of Arch.”
“The story is intact. The execution is high-quality and hits the right high notes. It all comes to fruition with a CE mark or a buyout, and the company is worth several times its present regressive market cap. Arch seems to have made no further moves toward uplisting, which frankly could triple share price by making $ARTH available to institutions.”
“$ARTH is creating in essence a new field of medicine, and new rules of the game and guidelines have to be constructed, nay, derived and invented, to support it. I prefer them making good choices to fast choices. I hashed through in my mind how, although one infers AC5 will work great guns to stop major GI hemorrhage, devising clinical trials to support and justify a transition to it will be complex and expensive….even though they have an obviousness to them. Norchi will likely spend the remainder of his career fine-tuning the utilizations of the MIT family of patents.”
“Norchi is a product of a small unknown medical school in eastern Ohio, not a good one. Doesn’t mean he’s no good, but rather that he may have been a late bloomer in college. If he went to this school, it’s because he had no other options. Since that time, I feel Norchi has been desperate to prove himself in the form of successively higher accomplishments. He got into the best medical residency he could under the circumstances, and busted his backside, and made it to chief resident—-hard to do. Then he grabbed an Ivy MBA. Then he buddied up with Dr. Ellis-Behnke, who is a hot and respected academic property in materials science, and got his name on a patent. He ran a healthcare mutual fund. At every stage, Norchi is trying to add to his stature and respectability, and he has the personality type that if he did something to fleece or scam people, I don’t think he could face himself in the mirror. He wants to be a star and to be regarded as honest. And as I see it, he is. I like him….he is decent and real, and fun to brainstorm with. He has a good head. He loves to laugh at good jokes.”
“AC5 is right now being manufactured reliably, reproducibly, and at a highly feasible cost. A competent, well known, high profile contract manufacturing organization has been secured and has signed on the dotted line. None of the amino acids that compromise it or their sidechain moieties are made unstable by common environmental factors, and neither are they reactive. The shelf-life of lyophilisate is indefinite.”
$ARTH (fp) – Thanks for the update Cleveland, I appreciate your technical and financial analysis you provide. I believe in the science behind $ARTH, but I am concerned about TNs ability to meet dates. If the FDA approval is not fast tracked and approval is delayed, more cash may need to be raised and we will see a large sell off. I don’t want to see this happen, but if it does I may consider it another buying opportunity.
Thank you, Cleveland. Amazing what was said – not only here, but on Twitter as well – especially between July 11, 2017 and December 18, 2017, and the 180 reversal in January 2018. (see $ARTH).
$ARTH I agree completely. I understand I was blamed this weekend for everyone owning and that I dominated the boards or something like that. It sounds like a ridiculous fairy tale. His statements for years on $ARTH were way over the top on the science. Hey look $ARTH has 50 patents….. amazing. Free to talk about anything here. Doc has now supported Stock Gumshoe. What a twist of fate…. CLRB today !!!!!!!!!!
Cleveland, I can’t speak for anyone else, but until/unless you apologize for the way you denigrated and vilified some of the folks here–including myself–for having the temerity to question KSS’s omniscience, I at least will have a hard time accepting your sincerity, and will have no interest in interacting with you. I do find it someone ironic that you have been (apparently) discarded like three-day-old garbage after willingly and enthusiastically serving as his enforcer here for so long. Despite the above, I am truly sorry for the way you’ve (again, apparently) been treated over there. Everyone deserves to be treated with respect.
I would probably enjoy discussing $ARTH and $CLRB with you, but the ball’s in your court.
#Cleveland Apology
Glad you brought it up. I was thinking about it. I do apologize to you and Hippockets and all. I was being LOYAL to Dr. KSS. The only one that was. Big mistake. As I documented no one has done more than I for him. This also was a huge mistake on my part. Huge. I had many warning signals.
“I am the person who raised $27,684.44 for travel expenses in 2017 from 105 people. I am the person who wrote a check for $ 1,000 to him. I am the person who found Cohbar CWBR. I was in his group of six and know everything about it. I assisted in getting the present website up and running and obtained many of his documents for Paypal to begin functioning. Has anyone done more than I? He cannot rewrite what happened so he can feel superior. Just not going to happen. Everyone knows the truth because it is all here.”
See Dr. KSS https://www.stockgumshoe.com/2017/11/microblog-discussion-page-for-arch-therapeutics-arth/comment-page-2/#comment-4983867
He has told the biggest fairy tale about me and slandered me and caused much harm. There probably has been a campaign with his merry band of six to discredit me. I will get to the bottom of it. I understand completely how they operate.
You have to understand that I am an extremely loyal person. He never appreciated anything. Nothing. Should have been warning sign to me.
Thank you. Apology accepted. Welcome back.
#ARTH wow > Turn about is fair play?
🙂 You always, always and #ALWAYS reap what you sow! 🙂
🙂 #Best2ALL! And yes, that includes you. 😉
Ben: He apologized. Let’s move on. Cheers!
$CLRB Only on Stock Gumshoe !!!!!!!!!!!!!!!!!!!!!!!!!!
I am going to vent today on Cellectar Bioscience ($CLBR) which I spent a lot of time analyzing over the years.
This makes my blood boil.
So there is 17,708,558 shares outstanding. Tiny !!!
$ 17 million market cap company. Raised since inception $ 94 million. So for every dollar raised it is now worth 18 CENTS. Some believe this is good ?? This is the Cleveland RATIO !!
On July 12, 2018 they are voting for a 5:1 to 10:1 REVERSE STOCK SPLIT
The Reverse Split will bring the shares outstanding down to 1,770,885 to 3,541,710 shares. REALLY????????????
I declare CLRB a PERENNIAL Reverse Stock company (like $AYTU).
6/13/14 20 for 1 REVERSE SPLIT
3/7/16 10 for 1 REVERSE SPLIT
The excuse the Company has to always do yet another reverse split is the depressed stock price. This is the PERENNIAL problem !!
I previously did a capital analysis summary for $CLRB. The $CLRBZ warrants at $3.04 8/20/21 will become $15.25 with a 5:1 reverse split and $ 30.40 with a 10:1 reverse split. Ouch !!!! Employee options same effect.
They are preparing a capital raise after the split. So whoever participates will own the company (until the next revere split). Look what little management owns.
Expect a call from Mr. Caruso to spin his “new” company.
So management has never owned much in terms of shares OR options. I always wondered why on the options? IMHO they always realized there would be another reverse split. No point in owning options.
https://www.sec.gov/Archives/edgar/data/1279704/000114420418034439/tv496569_s-1.htm
$CLRB wow > https://www.stockgumshoe.com/2018/02/biotech-discussion-continued/comment-page-11/#comment-4980268 #Best2all
$CLRB caving in today. Look at the adjusted price of the warrants. They will never get there. New biotech lesson about management owning little stock AND employee options. I also never liked the joint ventures they were doing with no cash to $CLRB.
Believe $ARTH is derisked and also $DMCAF. Have writeup in moderation.
I only joined 15-16 months ago. But Cleveland has always produced the goods without the drama. It can be hard to judge people sometimes just off of internet posts. Sometimes you can get hoodwinked. But never Cleveland. Straight shooter all the way. Glad he is back.
#Cleveland apology
When I read Cleveland’s postings and stm’s comment, I was getting worried that we SG bystanders were going to be dumped into the ugly abyss of anger-retort-counter retort. I don’t come here to have my emotions churned up in that manner.
HOWEVER, you both handled this exchange with maturity and I thank you from the bottom of my peace-loving heart.
Now, back to business.
Way to go STM and Cleveland! Civility is awesome, especially when we disagree.
That being said, what is up with a r t h? I am not privy to anything on KSS board and will not be in the future LOL so I don’t know what has been discussed about Arch. I owned a ton of shares at one time and have taken profits and reentered with a smaller but still sizable position when it got below .27.
So, can anyone shed any light on what is going on?
$ARTH Doc’s group of six monitor this board. I got kicked off the forum for no reason. I got bits and pieces that he blamed me for everyone owning $ARTH and that it was I somehow controlling his boards talking about $ARTH. Sounds Bizarre.
We all know that there is no truth in that. Right here in Stock Gumshoe you can find these:
“We get to cover and track a lot of cool stories here, but this is still the most important biotech storyline of our time in my opinion. Long $ARTH.”
“But in Arch’s case, in every instance, they are thinking fully, they are dreaming big. They plan to wreak themselves upon life with AC5. Whether your premise is sell-side or buy-side, these shares seem a ridiculously good place to be. They won’t pay off gradually, but rather the rewards will come in epochs, as seismic shifts occur in Arch’s landscape as a result of its labors.”
“I still think ARTH is doing primo science. It’s among the best protein chemistry in the history of mankind.”
“Arch is in full possession of the most fundamentally brilliant piece of protein chemistry any of us will see in our present lifetimes.”’
Read this to understand why he is slandering me and discrediting me.
https://www.stockgumshoe.com/2017/11/microblog-discussion-page-for-arch-therapeutics-arth/comment-page-2/#comment-4983831
No one should post anything from the DEN here. He will cut your throat and cut you off. Please do not post anything from there. I have no interest in seeing.
You bring up a point that he ignores. People made MORE money on $ARTH over the years than any other stock on this forum by a mile. You could buy at $.20 for a year and a half. This forum owned millions of shares.
$ARTH ow > Excuse me; isn’t that what you just did in your last post? #Re: $CLRB ow ooops “CLBR” https://www.stockgumshoe.com/2017/11/microblog-discussion-page-for-arch-therapeutics-arth/comment-page-2/#comment-4983896 🙂 Speak the #truth and the truth shall set you #FREE! 🙂 #Best2ALL!
$ARTH
Cleveland, were the messages you’re talking about posted on the Pro section of the new KSS BIO site? I’m just a regular member over there and don’t have access to content for Pro subscribers only.
Penny
Sorry I have no idea. That was always confusing.
$ARTH ow, $CLRB ow > How can that be? “I was in his group of six and know everything about it. I assisted in getting the present website up and running…?” https://www.stockgumshoe.com/2017/11/microblog-discussion-page-for-arch-therapeutics-arth/comment-page-2/#comment-4983831 Notice “I” was used 11 times in the last 14 sentences, of that post. #Best2ALL!
From a post of yours above…..
“To moi, $ARTH has and shall continue to be nothing more than a distraction, with large opportunity costs,…”
O.K You are entitled to your opinion. But……
Why are you still over here blowing smoke about it.
Go do something more productive…….
Get a grip Gar8ful. I remember you chiding me, no it was more of being hateful, about not sticking to the point of this forum which is stocks. Now I can give it back to you. You are ungrateful to those who helped build this forum unless it is you shouting from the rooftops which half of the time I don’t know what the heck you are talking about. Half text, and hal emoticons
Hey Richardo
My like thinking friend. Missed you.
You have always posted my exact thoughts. Amazing.
Don’t give it any brain space.
My friend as well Cleveland. A fan and will always be a fan. Those of us who have been a Gummie for a long time, have long memories. Your thoughtful, incisive, and honest comments were always appreciated. You were a voice in the wilderness for a long time, but never gave up, or have given up even though at time you were unappreciated. Kudoes
Folks, for this forum to be successful moving forward, we all have to forget the old divisions. If Cleveland and I can put things behind us, I have faith that the rest of us can, too.
Not trying to be preachy, just pragmatic. This should go back to being a welcoming space where we can disagree respectfully and then share a beer.
Glad to, billy. Norchi lined up all the people needed for the sensitivity test, got them enrolled, and started the test last week. The FDA must have asked for a three-month test. Of course, it is open-label, so ARTH can accumulate data as they go. At the end of the test in mid-September they can write it up and resubmit the 510(k) to the FDA. Norchi has committed to do that by the end of September. At the recent LD Micro conference he said ARTH expects a decision around the end of 2018 or very early next year, which means the FDA must have told him they’d give it a quick review.
Norchi also said he’d file the CE Mark application “around the same time” as the 501(k) goes to the FDA, although he later said “that’s a second-half event.”
He also pointed out that about $4 million of the outstanding warrants are in or near the money, implying to me that he might not have to do a capital raise until after AC-5 is approved.
FWIW I think the stock is dirt cheap with a revolutionary technology. I believe the clinical trial was delayed by bureaucracy at CURAM, not by Norchi. I think the screw-up on the CE Mark filing was caused by the AC-5 manufacturer, not by Norchi. I think the delay in getting the clinical trial results into print was caused by the author and the peer-reviewed publication process, not by Norchi.
You can argue that Norchi should have hired a QA person sooner to avoid the CE Mark problem. You certainly can argue that he should have avoided ipssing off DR KSS with that phone call, no matter how frustrated he was with his FDA consultant blabbing to a member of this group. But as Cleveland pointed out, you can’t argue that this is not a stunning technology about to enter a huge market, brought to fruition on peanuts in R&D spending.
I’m biased, ARTH is now derisked and my biggest position. It’s a shame the man who found the company and vetted the technology won’t benefit from what might be the biggest winner he ever recommended.
I’d like to discuss $CLRB, but perhaps we could take it to a different thread?
regarding $ARTH, to be honest, I don’t care one whit what is being said at that other site. I do care about how their story may play out, however. It seems to me that much of the drama regarding their company, progress, and share price is due to an incomplete picture of what is going on over there, and a lot of assumptions being made among retail investors. As a lawyer, I know that execs have to be very careful what they tell investors that is not publicly released, and I’ve gotten the impression from the beginning that Norchi has taken this very seriously, and therefore doesn’t reveal anything that might be considered inside information. And that this may have irked KSS, and been misinterpreted by him as nothing being done.
[Aside: I want to contrast that with something which really made me nervous at the outset regarding CohBar, which is when KSS stated that the CWBR CEO or COO or CFO showed him slides and/or images and/or data that “amazed” him–either those slides were publicly available, in which case he should already have seen them on CWBR’s web site, or they were breaking the law, period. Only he knows which.]
I have to trust that the skin irritation studies are the way they’ve been described: that they are simple, that they will take just a few weeks to carry out, and that they will answer the FDA’s questions in full. I’m willing to wait to see.
HOWEVER–as i understand it, they will soon need to raise capital. Seems to me that the prudent thing to do is expect to sell shares either when they submit the study or when the FDA grants the application, then look to rebuy sometime next year, after the invariable share price dip.
If this product works, the money is in internal use, not external use. Seems that approval for internal use is still a few years away.
Anyway, that’s my quick and dirty take.
STM, I’m always interested in your posts and completely agree that Norchi is extra careful about inside information. From his years running a biotech fund, he’s also very knowledgeable about the issue.
The sensitization study takes three months, not a few weeks. When he has to raise money depends on how many warrants get exercised. He owns 10% of the company and other insiders own an additional 10%, so they don’t like dilution anymore than we do.
I disagree about the value of external use. Pressure ulcers (bed sores) affect 2.5 million people a year in the U.S. and some patients die from opportunistic infections. Diabetic foot ulcers affect 1.0 to 1.5 million patients a year and as I remember account for 40% of all foot amputations, at great expense to Medicare and suffering to patients. Then there are burns…
Over $15 billion a year is spent on wound care products. As Norchi says, if a Band-Aid works, use it. If not…AC-5?
Thanks, John!
$ARTH $CWBR
STM
To be honest I hope we can just be on one thread. Gets too confusing.
Dr. Norchi is the most careful public executive about insider information. I don’t think that irked Dr. KSS. He understood that completely. Dr. Kss is very professional and respects that in others.
I think Dr. Kss created the $ARTH monster by his over the top comments about the science of $ARTH for several years. People purchased positions with the thought of holding forever. People here asked day in and day out the same $ARTH questions. It wore him out. He created a separate forum. He ignored the second forum and it became a zoo with people trading $ARTH with scare tactics, etc. I think that JohnM said the same thing basically earlier which I agree with.
People that have cashed out have made an enormous amount already in this forum. I believe it is already the biggest realized winner by a mile. I guess Dr. KSS is now blaming me for the $ARTH debacle which is his view. How many times has he urged and basically told everyone to SELL. Know that he does not give “investment advice.” It has gotten personal for him. They are quick to call this a Cult Stock. Well what is APTO, CWBR, etc ??? He is probably flipping out that $ARTH is even being discussed here. Profanity this and profanity that.
I talked with Dr. Norchi about the “event” that triggered Dr. KSS and he did not see it the same way. So I wrote a big piece on $ARTH which I put on the DEN. It explained a lot. I cannot copy here but could try to rewrite in a separate and different way. Not sure anyone would be interested.
I was with Doc at Cohbar. I showed him those public slides from their website that he saw for the first time. He was blown away. He went nuts. He just did not take the time to review before we made the trip. Nothing wrong here at all. Everyone extremely professional and impressive. It was one great due diligence trip.
Where you went wrong is that we did not have the complete story out there to do due diligence. I posted all my stuff after the conference call. IMHO you had opinions without doing real detailed due diligence. This was probably a mistake on your part. Anyways it will be one of the greatest situations ever IMHO. He flipped out and I reacted to his negative comments in an over reaction fashion for me. For this I apologize.
Thanks, Cleveland. To add a little color to my thinking, it was not concerns about $CWBR that worried me as much as doubts about KSS, but I wanted to keep that to myself and not appear that I was accusing him of any wrongdoing, especially since it was based on a feeling and nothing tangible. My memory is a little hazy, but at the time he had just touted several stocks that either went south, or he suddenly changed course on and possibly lambasted forum members about, and it gave me concerns about either his honesty or his mental state. Until then, although I knew his full background, his past didn’t bother me in the slightest. I don’t remember which stocks they were, or the exact circumstances, but the situation caused me to decide to not rush in to any further recommendations. Then he started a pitch that, in all honesty, if it was in one of Travis’s write-ups about some financial newsletter everyone would have been in hysterics: My best recommendation ever! This drug could cure every disease known to man and allow you to live to be 120! Everyone needs to buy this stock now before it is too late! So I was being cautious, especially after seeing how the stock ran up in the days before he touted it. I probably shouldn’t have said anything, but I think part of me wanted to see how he’d react, and part of me believed him when he said that he “wanted to hear everyone’s opinions on it.” Given all this, the fact that he was furious with me for indicating that I would not buy stock IMMEDIATELY was a huge red flag. Now, I’m not saying that he was doing anything unlawful or unethical here (chances are, probably not), but these factors together were enough for me to take a step back and really question the information he was telling us. After all, it is my money, and I had to be 100% comfortable to invest it, and I clearly wasn’t, not any more. I hope $CWBR is successful, both for them and for all the Gummies who are invested, but in light of how he destroyed $ARTH’s market cap, I’m going to continue to wait until the volume picks up on this one (which it has started to).
After he destroyed $ARTH, I sold several of my other biotech holdings he had touted that had low volumes, in fear that he could do the same to them. I kept $CLRB, though, in part because he seemed to be no longer touting it.
Hope that helps.
#KSS
No it had nothing to do with buying the stock. Zero.
It had everything to do with the fact that we had just got off the conference call ten minutes and spent months doing due diligence and had yet to complete our due diligence reveal.
It was impossible to do any real due diligence in ten minutes.
As I have said a million times I could care less if anyone owns any stock that I own.
There is a checklist of things to consider with KSS stocks.
He is an absolute genius on the science. He can discuss the science with company insiders easily. Where he falters big time is the financial side. That is where I came in. Few people have my financial experience. That is why we were a great team. IMHO his insecurity got the best of him.
Thanks, Cleveland. That is all very helpful.
You do realize CWBR is already a success? Stock has already doubled since he initially recommended it…
I do. The important thing is sleeping at night, not FOMO. I was deeply uncomfortable with the way it was being touted. Perhaps that was his fault more than any concerns about the company, but in all honesty, in light of the events that have transpired since then, leading to his Exodus from stock gumshoe and all the associated drama, including to the way he has turned on former confidants, was I wrong to be wary of him? This could easily have been another $halo: going from “this is a twenty bagger!” to “get out now” overnight.
Again, I’m happy for everyone who has profited. I’m not second guessing my decision.
Cleveland – I’m sure most that follow this thread would be interested in your write up. Thanks for taking time to offer your thoughts.
v/r
jdd